Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
HCW Presentation September 13, 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
HCW Presentation March 9, 2021
SVB Leerink Presentation Feb 24, 2021
JPM Presentation Jan 14, 2021
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Press Releases
ObsEva Announces Progress on Restructuring Initiatives
press release
September 13, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 13, 2022 –…
Read moreObsEva Receives Nasdaq Non-Compliance Notice
press release
August 22, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August…
Read moreObsEva Files Second Quarter 2022 Financial Statements
press release
August 17, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – August…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2022
May 18, 2022
ObsEva Annual General Meeting 2021
May 28, 2021
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Progress on Restructuring Initiatives
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 13, 2022 –…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
